Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantharidin - Verrica Pharmaceuticals

Drug Profile

Cantharidin - Verrica Pharmaceuticals

Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTH

Latest Information Update: 08 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verrica Pharmaceuticals
  • Developer Torii Pharmaceutical; Verrica Pharmaceuticals
  • Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Molluscum contagiosum
  • Phase II Genital warts; Warts

Most Recent Events

  • 05 Feb 2024 Verrica Pharmaceuticals files lawsuit against Dormer Laboratories for false advertising and unfair competition
  • 04 Jan 2024 Verrica Pharmaceuticals receives minutes of type C meeting held with the US FDA to discuss the Phase III clinical development plan for Cantharidin (YCANTH) for the treatment of common warts
  • 15 Dec 2023 Efficacy and adverse events data from phase III clinical trials in Molluscum contagiosum released by Verrica Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top